China Resources Pharmaceutical's true inflection point: not profit growth, but the return of "drug content"

The annual report disclosure season for 2025 is nearing its end. Recently, China Resources Pharmaceutical (03320.HK) triggered a strong reaction in the secondary market with its results: revenue up a slight 4.6%, profit attributable to shareholders surging 20.7%, and a doubling of its dividend. After the results, its share price jumped by more than 11%.

This kind of divergence—“earnings look flat, but the stock price is strong”—often means a deeper change is underway: capital is no longer trading the company purely around its current growth rate, but is instead重新 pricing the company’s long-term structure.

Against the backdrop of the industry, this shift is even more targeted. On the one hand, centralized procurement becoming the norm and医保 budget controls continue to compress profit margins under the traditional distribution model. On the other hand, in 2026, the first two sessions (Lianghui) will elevate biopharmaceuticals as a national emerging pillar industry; innovative drugs and TCM consumption, as well as high-end manufacturing, have become the areas where policy direction and capital are converging.

In such a cycle shift, it is only natural for valuation logic for pharmaceutical companies to change in parallel. So what exactly has changed for China Resources Pharmaceutical?

What’s rising is not profit itself, but expectations for the quality of future profit

For a long time, the capital market has held two deeply rooted biases in how China Resources Pharmaceutical is valued: first, nearly 80% of its revenue comes from pharmaceutical distribution, which makes it be regarded as a “logistics giant” with thin margins and little imagination; second, although the Chinese medicine segment is large, it is believed to be traditional enough, but with insufficient innovation.

As a result, China Resources Pharmaceutical has long enjoyed ultra-low valuation multiples similar to those of utility stocks.

But the 2025 financial report sent a key signal: control over earnings is quietly shifting from the distribution end to the manufacturing end. Even though distribution business still accounts for 78.7% of revenue, the contribution structure of profits has undergone a fundamental qualitative change.

Data shows the group’s overall gross margin increased by 0.7 percentage points to 16.5%. While that improvement looks small, based on a revenue base of over RMB 100 billion, it implies the release of several billions in pure profit. The core of this change is an increase in “medicine-in-the-mix,” meaning the accelerating contribution rate of the pharmaceutical manufacturing segment.

Supporting this shift is a clear, fully formed dual-engine structure.

On one end, the “cash cow base” is made up of the TCM and OTC brand portfolio. Core assets represented by China Resources Sanjiu, Dong’e E-jiao, and Jiangzhong are, in essence, consumer-product attributes such as pricing power, repurchase rates, and brand mindshare. In an environment where centralized procurement price pressure has become the norm, these products are not completely constrained by the “only low price” logic of centralized procurement, and they form a stable high-gross-margin source of earnings for the group.

On the other end is an offensive engine centered on M&A and License-in. Unlike Biotech, which depends on high-risk original R&D, China Resources Pharmaceutical has chosen a more deterministic path: acquiring mature assets, integrating R&D capabilities, and then leveraging its own channel system to achieve rapid volume growth. The integration of Tsangshi Pharmaceuticals into China Resources Sanjiu is a typical example of this logic—not only does it fill out the prescription-drug and innovative pipeline, but it also directly changes the profit structure.

More importantly, this structure is sustainable. TCM consumer products provide stable cash flow, while innovative drugs and M&A introduce growth elasticity; the “use the old to support the new” combination gives the company both a safety cushion and room for imagination.

At the same time, the company’s final dividend doubled significantly year over year, and the marked increase in payout ratio is often the strongest signal that management has strong confidence in the quality of cash flow and the certainty of future earnings.

Therefore, what the market is rising for is not the absolute level of profits in the moment, but rather expectations for the quality of future profits.

This transition from a low-margin circulation-scale model to a profit-driven model directly changes its valuation anchor. China Resources Pharmaceutical is no longer a low-multiple wholesaler; it is a pharmaceutical company with a product “moat” and a platform-like structure.

In the deep waters of industry differentiation: why did China Resources Pharmaceutical step up?

If you place China Resources Pharmaceutical side by side with peers across the industry, the value of this change becomes even clearer.

In recent years, the core logic of China’s pharmaceutical distribution industry has been to compete on scale. But against the backdrop of centralized procurement becoming normalized and医保 controls strengthening, this logic is rapidly losing effectiveness. The larger the scale, the more likely it is to fall into a low-profit trap.

This is also why, in 2025, several leading pharmaceutical giants showed clear differentiation. Sinopharm Holdings remained large in scale but saw growth stagnate, and even experienced local declines—the classic “big elephant hard to dance.” Shanghai Pharmaceuticals relied on its industrial segment for profit growth, but distribution efficiency dragged down overall performance. TTK (Jiuzhou Tong) relied on private-sector mechanisms to break through in the off-hospital market, but it lacked upstream manufacturing assets, making its profit ceiling clearly defined.

Behind all this is a thorough industry logic switch: the pharmaceutical industry has entered a new stage of “competing on structure.”

China Resources Pharmaceutical’s unique advantage lies in the fact that it has all three capabilities at once:

First is product strength at the manufacturing end. The TCM segment has a TCM “carrier group” made up of five major listed platforms, including China Resources Sanjiu, Dong’e E-jiao, China Resources Jiangzhong, Tian Shi Li, and others.

In 2025, although some subsidiaries faced pressure on revenue, the profit side generally demonstrated strong resilience. Dong’e E-jiao continued value restoration, with double-digit net profit growth. China Resources Jiangzhong, despite a slight decline in revenue, delivered a 15% jump in profit by optimizing its product mix. Against the backdrop of overall pressure on the TCM industry, such counter-cyclical performance itself is a barrier.

Second is channel strength at the distribution end. A nationwide distribution network gives it the ability to quickly ramp up product volumes, which is especially critical in the era of innovative drugs and OTC consumer products—whoever controls the channels controls commercialization efficiency.

Third is integration capability at the capital end. It has shifted from simply “buying assets to build scale” to “managing assets to improve efficiency.” Whether it is the profit repair after Tian Shi Li was consolidated, or the governance restructuring of Kunming Pharmaceutical, the essence is the amplification of asset value through organizational and operational capabilities.

This “three-in-one” results in a company that is neither as low-profit as a pure distributor nor as high-risk as a pure pharmaceutical enterprise, instead forming a structure that lets it attack when conditions are favorable and defend when needed.

More importantly, the source of profits is moving from the “hospital end” to the “consumer end.” With the rise of TCM health supplements and OTC health consumer products, China Resources Pharmaceutical is gradually building pricing power with end consumers.

That means it is no longer entirely dependent on the医保 and centralized procurement systems, but instead has a portion of “market-based pricing power.” This is particularly important in today’s pharmaceutical policy environment.

That is also why the company’s revenue growth rate can remain relatively ahead within the industry. In other words, China Resources Pharmaceutical’s advantage is not only “more stable,” but also “structurally better.”

Behind slimming down and focusing is an even bigger industry migration

Zooming out further reveals that China Resources Pharmaceutical’s turnaround is essentially a microcosm of major trends in China’s pharmaceutical industry.

Currently, China’s pharmaceutical industry is undergoing deep migration along three main lines:

First, the logic of traditional distribution is failing. Centralized procurement and医保 budget controls are compressing profits in the circulation layer, and a business model that relies solely on scale is losing its support.

Second, innovative drugs and high-end medical devices are becoming core assets. In 2026, the first two sessions will elevate biopharmaceuticals to an “emerging pillar industry.” Innovative drugs and high-end medical devices become the focal points of both policy and capital, and the industry’s valuation framework starts to move toward “hard technology.”

Third, the value of TCM is being rediscovered. Driven by aging and consumption upgrades, TCM is returning from a “policy-edge asset” to the growth main line. Policy clearly states that by 2030, the total industrial output value of the TCM industry will reach RMB 1.8 trillion, opening up long-term space for leading companies.

China Resources Pharmaceutical’s strategic moves essentially bet on all three trends at the same time.

On one hand, by divesting non-core assets and optimizing its structure, it reduces reliance on low-return businesses. On the other hand, it increases investment in innovative drugs, TCM brands, and high value-added segments, achieving a migration from a “heavy-asset scale” model to a “light-asset efficiency” model.

More importantly, it begins to get ahead of new growth variables: AI enabling R&D and operational efficiency; incremental markets brought by pharmaceuticals going overseas; and increased concentration driven by the standardization and branding of TCM.

These variables determine not short-term performance, but the growth boundaries for the next decade; they also determine whether China Resources Pharmaceutical can truly upgrade from a traditional pharmaceutical company into a pharmaceutical technology platform.

Conclusion

China Resources Pharmaceutical’s financial report may not be perfect. Revenue growth remains steady rather than rapid, and some subsidiaries are still in the adjustment phase. But it at least shows one important thing: China Resources Pharmaceutical is getting rid of the label of a “low-valuation distributor” and transitioning into a “high-quality pharmaceutical platform.”

For investors, this means that in the short term, valuation repair will come from improvements in structure rather than explosive growth in performance. In the mid term, as industry differentiation intensifies, companies with high “medicine-in-the-mix” and strong pricing power will continue to enjoy a premium. In the long term, the dual engines of innovation and consumption will determine the ceiling of its market capitalization.

The most critical judgment is that, in the era of “quality competition” in the pharmaceutical industry, whoever can掌握 product strength and pricing power will have a future.

Source: Hong Kong Stocks Research Society